Humacyte, Inc.

US$0.45As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:HUMAHealthcare
Country USA
PE (Fwd) •••
TSR 6Y CAGR (41.34%)
Div yield —
ROE (547.87%)
Biotechnology
Beta (5Y) 2.68
PE TTM —
TSR TTM (73.16%)
Mkt cap US$124.5M
ROIC (74.17%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$0.461
2.87%
(71.54%)
Hold 3|2|1|0|3
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.01
0.01
0.01
0.01
27.24%
13.07%
2.41%
5.28%
Revenue$M
11.27
11.67
12.06
12.73
13.19%
11.86%
9.86%
15.93%
Peers (US$124.5M)
Cap (US$)
PE
124.0M
—
124.7M
—
Capital
TTM
5Y
10Y
Leveragex
1.143
5.524
4.808
EBIT/Intx
0.329
0.453
0.298
Own earn%
17.78
32.20
46.72
Sh yield%
45.68
49.79
49.39
Owners
Insiders/Inst%
6.39
34.97
Short interest%
1.87
SBC / revenue%
4.88
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
9
Op margin range%
7–12
$1 testx
—
Incr. ROIC%
8